[go: up one dir, main page]

WO2009063364A3 - Modulators of urotensin receptor and methods of use thereof - Google Patents

Modulators of urotensin receptor and methods of use thereof Download PDF

Info

Publication number
WO2009063364A3
WO2009063364A3 PCT/IB2008/054633 IB2008054633W WO2009063364A3 WO 2009063364 A3 WO2009063364 A3 WO 2009063364A3 IB 2008054633 W IB2008054633 W IB 2008054633W WO 2009063364 A3 WO2009063364 A3 WO 2009063364A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulators
compounds
urotensin
receptor activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/054633
Other languages
French (fr)
Other versions
WO2009063364A2 (en
Inventor
Daxin Gao
Chengde Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of WO2009063364A2 publication Critical patent/WO2009063364A2/en
Publication of WO2009063364A3 publication Critical patent/WO2009063364A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are compounds that are modulators of urotensin-II receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of urotensin-II receptor activity wherein the disease is a cardiovascular disorder, atherosclerosis, renal failure, nephrotoxicity and diarrhea caused by antineoplastic agents, post-myocardial infarction, pulmonary hypertension, diabetes or a CNS related disease.
PCT/IB2008/054633 2007-11-13 2008-11-06 Modulators of urotensin receptor and methods of use thereof Ceased WO2009063364A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US297407P 2007-11-13 2007-11-13
US61/002,974 2007-11-13

Publications (2)

Publication Number Publication Date
WO2009063364A2 WO2009063364A2 (en) 2009-05-22
WO2009063364A3 true WO2009063364A3 (en) 2009-07-02

Family

ID=40578657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/054633 Ceased WO2009063364A2 (en) 2007-11-13 2008-11-06 Modulators of urotensin receptor and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009063364A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Also Published As

Publication number Publication date
WO2009063364A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
FR2911063B1 (en) RUPTIBLE BRIDGE STRUCTURE FOR STENT, AND STENT INCLUDING SUCH BRIDGE STRUCTURES.
GR1007108B (en) Methodology for the removal of non-organic contents (chlorime, sulfur, potassium, sodium) from agricultural, forestal and urban biomass
WO2011062803A3 (en) Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
IL191010A0 (en) Diaryl ureas for treating pulmonary hypertension
EP2220074A4 (en) 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EP1973995A4 (en) Process for upgrading heavy oil using a highly active slurry catalyst composition
WO2009029883A3 (en) Methods and compositions for modulating t cells
EP2362862A4 (en) Modified sulfur binder and the fabrication method thereof, hydraulic modified sulfur material composition and the fabrication method thereof or combustible modified sulfur material composition and the fabrication method thereof containing the modified sulfur binder
EP1885660A4 (en) PRODUCTION OF PELLETS FROM LIME FINISHES AND ASPHALT-COMPATIBLE BINDERS AND METHODS OF USE IN ASPHALT PRODUCTION
WO2005118878A3 (en) Methods of screening for cell proliferation or neoplastic disorders
GB0512183D0 (en) Improvements relating to the refining of waste oil
PL1858877T3 (en) 1,3 substituted diaryl ureas as modulators of kinase activity
WO2008079352A3 (en) Antibodies to cd200r
EP1867659A4 (en) Antibody reactive specifically to age derived from 3,4-dge
EP2174134A4 (en) BIOMARKERS FOR DIABETES, OBESITY, AND / OR HYPERTENSION
AP2360A (en) Versatile high load concentrate compositions comprising metaflumizone for control of ecto-parasites.
WO2010123956A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
WO2009063364A3 (en) Modulators of urotensin receptor and methods of use thereof
FR2917955B3 (en) CURVED BABY BED WITH INCLINED ANGLE PIECES
FR2913903B1 (en) INSTALLATION FOR ASSEMBLING DORMANT FRAME ELEMENTS.
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2005052125A3 (en) 24p3 receptors and uses thereof
FR2882812B1 (en) REFRACTORY TILE, IN PARTICULAR FOR A GASIFIER.
PL1743978T3 (en) Method for the formation of a load bearing construction
FR2917963B3 (en) PROSTHETIC ASSEMBLY FOR THE ARTICULATION OF THE SHOULDER.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08849382

Country of ref document: EP

Kind code of ref document: A2